First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
The partnership initially will focus on cardiovascular and kidney diseases
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
Subscribe To Our Newsletter & Stay Updated
